Comets Braithwaite Suspended Indefinitely

Posted on by

March 19, 2015 - Major Arena Soccer League (MASL) The Major Arena Soccer League today issued a statement and announced suspensions following events that took place surrounding Game 2 of the Eastern Conference Finals Sunday in Independence, Missouri.

Missouri Comets defender Andre Braithwaite will be suspended indefinitely by the league for his head-butt as teams were shaking hands after the game. He can apply for reinstatement following the 2015/16 season. The Comets released him immediately following the game.

Comets defender Brian Harris, who was given a red card for a reckless slide tackle with 12 seconds remaining in the game, will be suspended for the first three games of the 2015/16 season.

Comets defender John Sosa, who was given a red card for verbal abuse, will be suspended for one game to be served at the beginning of the 2015/16 season.

"The MASL cannot condone physical play or actions where the intention is to cause harm to other players," said MASL Commissioner Kevin Milliken. "These incidents have taken the spotlight off what was a competitive series between two of the league's top teams, and marred what had been an outstanding season by the Missouri Comets."

Following Game 2 of the Baltimore/Missouri series there was an implication by a coach of improper communication between an owner and a referee prior to the game. After reviewing the allegations and watching the video of the game, the league did not find any merit to the allegations. Behavior of others surrounding this game is still being investigated.

Discuss this story on the Major Arena Soccer League message board... Digg this story Add to Del.icio.us

Read the original post:

Comets Braithwaite Suspended Indefinitely

March 28 Is Military Night at the Aud

Posted on by

March 20, 2015 - American Hockey League (AHL) Utica Comets The Utica Comets will honor the men and women who have served, and continue to serve, our country with Military Night on Saturday, March 28. It is a night dedicated to raising funds and awareness for the Veteran's Outreach Center.

The Comets will wear special blue camouflage sweaters that will be sold during a live auction immediately following Saturday night's game.

The Comets are also offering military service members, including veterans, a special $12 ticket for any available seat to Saturday's game, against the Rochester Americans, when they show a valid military ID at the box office.

The National Guard will have a weapons display and games on the concourse for fans to compete and learn more about these branches of the military.

The UCD/ CNYVOC was formed to provide and conduct charitable, educational, social service, and housing services for veterans in need. CNYVOC is in the process of creating a resourceful, one stop facility in Utica for veterans residing throughout Central New York. When complete this facility would offer, among other services, transitional housing for homeless veterans with permanent housing for disabled and elderly veterans, plus a wide variety of other services.

Discuss this story on the American Hockey League message board... Digg this story Add to Del.icio.us

Follow this link:

March 28 Is Military Night at the Aud

New Novartis data show more Cosentyx-treated psoriasis patients achieved clear or almost clear skin (PASI 90 …

Posted on by

EAST HANOVER, N.J., March 20, 2015 /PRNewswire/ --Novartis today announced results from the CLEAR study demonstrating Cosentyx (secukinumab) improved skin clearance at Week 16 in significantly more moderate-to-severe plaque psoriasis patients compared to Stelara* (ustekinumab), a widely used biologic. The detailed findings were presented in a late-breaking research session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult patients with moderate-to-severe plaque psoriasis.

"As a clinician I have seen first-hand the impact that moderate-to-severe plaque psoriasis can have on patients' lives and the frustration some feel when they are unable to achieve clear or near clear skin," said Andrew Blauvelt, MD, MBA, President of the Oregon Medical Research Center and lead study investigator. "The CLEAR data are an important step forward for clinicians and patients as they demonstrate Cosentyx compares favorably to Stelara, a widely used biologic."

In this Phase IIIb study, Cosentyx met the primary endpoint of superiority to Stelara as assessed by the Psoriasis Area Severity Index (PASI) 90 response, known as clear to almost clear skin, at Week 16 (79.0% vs. 57.6%, P<0.0001). The secondary endpoint found 50% of Cosentyx patients achieved PASI 75 at Week 4 compared to 20.6% of Stelara patients (P<0.0001).

PASI measures the redness, scaling and thickness of psoriatic plaques, and the extent of involvement in each region of the body. Treatment efficacy is assessed by the reduction of the score from baseline (i.e., a 75% reduction is known as PASI 75 and a 90% reduction is known as PASI 90). PASI 90 is a higher standard of skin clearance compared to PASI 75.

In an exploratory analysis, completely clear skin (PASI 100) at Week 16 was achieved by significantly more patients treated with Cosentyx than those receiving Stelara (44.3% vs. 28.4%).

"Helping psoriasis sufferers achieve clear skin remains the goal for both patients and their physicians, yet many patients still do not achieve this," said Christi Shaw, US Country Head, President of Novartis Corporation and Novartis Pharmaceuticals Corporation. "The findings from the CLEAR study demonstrate that Cosentyx helps a majority of patients relieve the thick, red, scaling and extensive plaques that are common in those living with psoriasis. The data reinforce the importance of Cosentyx as a beneficial new treatment option, offering hope to psoriasis patients so they can take control of this often isolating disease."

The safety profile of Cosentyx was comparable to Stelara and consistent with previously reported Phase III clinical trials for Cosentyx. In the study, the most common adverse events (AEs) in the Cosentyx-treatment arm were headache (7.8%), nasopharyngitis (6.9%), diarrhea and fatigue (4.2% each), and arthralgia (3.9%). The most common AEs in the Stelara-treatment arm were nasopharyngitis (10.1%), headache (8.0%), arthralgia (4.2%), diarrhea (3.6%), and fatigue (2.7%). Infections and infestations were comparable between the Cosentyx and Stelara treatment groups (29.3% and 25.3%, respectively). Non-fatal serious adverse events in both treatment groups were the same (3%). No deaths have been reported, to date.

About the CLEAR studyCLEAR (Comparison to assessLong-termEfficacy, sAfety and toleRability of secukinumab vs. ustekinumab), a 52-week, multicenter, randomized, double-blind study, is a head-to-head Phase IIIb study initiated with Cosentyx, and compares the efficacy, long-term safety and tolerability of Cosentyx (secukinumab) versus Stelara (ustekinumab), in patients with moderate-to-severe plaque psoriasis. Twenty-four countries across North America, Europe, Asia and Australiaparticipated in the single study, with enrollment reaching 679 patients in record time.

The primary endpoint measured at Week 16 is PASI 90. PASI 90 is considered a more robust measure of the extent of skin clearance compared to the standard efficacy measures used in most psoriasis clinical studies, such as PASI 75. Additionally the secondary endpoint measured at Week 4 is PASI 75. PASI 100 at Week 16 was one of the exploratory endpoints. Week 52 data will follow in due course.

About Cosentyx (secukinumab) and interleukin-17A (IL-17A) Cosentyx (secukinumab, previously known as AIN457) is a human monoclonal antibody (mAb) that selectively binds to interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. It is the first IL-17A antagonist approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy).

Read the original here:

New Novartis data show more Cosentyx-treated psoriasis patients achieved clear or almost clear skin (PASI 90 ...

Kerala Tourism, Kerala Travel Packages, Kerala Tour Packages, Kerala Holiday Packages – Video

Posted on by


Kerala Tourism, Kerala Travel Packages, Kerala Tour Packages, Kerala Holiday Packages
Kerala Tourism , Kerala Travel Packages , Kerala Tour Packages All You Need To You About Kerala Tour,Kerala Tourism ,Kerala Travel Packages, Kerala Tour Packages , Kerala Holiday Packages...

By: TravelWithSmile.Com

Read more from the original source:

Kerala Tourism, Kerala Travel Packages, Kerala Tour Packages, Kerala Holiday Packages - Video

Friedrich Nietzsche and the Posthuman/Transhuman in Film and Television – Video

Posted on by


Friedrich Nietzsche and the Posthuman/Transhuman in Film and Television
Video Presentation: Babette Babich, "Friedrich Nietzsche and the Posthuman/Transhuman in Film and Television In: Michael Hauseller et al., eds., Palgrave Handbook of Posthumanism in Film and...

By: Babette Babich

Read the original here:

Friedrich Nietzsche and the Posthuman/Transhuman in Film and Television - Video

Stem Cell Therapy, Stem Cell Treatments, Stem Cell Clinics …

Posted on by

With the onset of Alzheimers disease, information transfer at the synapses (the connection between the nerve cells and extensions) starts to break down, and the number of synapses decreases significantly.

Autoimmune diseases are conditions in which the patients immune system generates cellular and antibody responses to substances and tissues normally present in the body.

In each condition there is chronic obstruction of the flow of air through the airways and out of the lungs, and the obstruction generally is permanent and may be progressive over time.

Diabetes is the condition in which the body does not properly process food for use as energy. When you have diabetes, your body either doesn't make enough insulin or can't use its own insulin as well as it should.

Multiple sclerosis (or MS) is a degenerative disease involving the deterioration of nerve cells. MS attacks the central nervous system (CNS), which is made up of the brain, spinal cord, and optic nerves.

Osteoarthritis, or degenerative joint disease, is the most common type of arthritis. It is caused by the degradation of a joints cartilage.

Parkinson's disease is a chronic progressive neurological disease that affects nerve cells (neurons) in an area of the brain known as the substantia nigra.

Rheumatoid Arthritis is an autoimmune disease that attacks the bodys own tissues, specifically the synovium, a thin membrane lining the joints. As a result, joint fluid builds up, causing pain in the joints and inflammation thats systemic.

Read the original post:

Stem Cell Therapy, Stem Cell Treatments, Stem Cell Clinics ...

Stem cell therapy may help treat type 2 diabetes

Posted on by

A human embryonic stem cell line derived at Stanford University.(REUTERS/Julie Baker/Stanford University School of Medicine/California Institute for Regenerative Medicine/Handout)

Type 2 diabetes is marked by insulin resistance, or the bodys inability to store sugar and convert it into carbohydrates for energy. Overcoming that resistance is the main hurdle scientists face in creating new treatment for the condition, but researchers in Canada have found a promising means for doing so: combining stem cell therapy and antidiabetic medication.

Type 2 diabetes accounts for nearly 95 percent of the 400 million diabetes cases worldwide. Current treatment often involves imprecise insulin injection, and can produce side effects like unwanted weight gain, gastrointestinal issues and low blood glucose levels. Eighty percent of Type 2 diabetes patients are overweight.

In the study, published Thursday in the journal Stem Cell Reports, scientists observed that transplanting pancreatic stem cells derived from human cells into mice with Type 2 diabetes symptoms, then administering common antidiabetic drugs, improved the mices glucose metabolism, body weight and insulin sensitivity three hallmark problems associated with the condition.

There have been similar reports looking at treatment of type 1 diabetes by stem cell-based replacement, and there are many people around the world who are interested in that, lead study author Timothy J. Kieffer, a molecular and cellular medicine professor at the University of British Columbia, in Vancouver, told FoxNews.com. Until this point, nobody to our knowledge had tested such a stem cell-based transplant study in a Type 2 diabetes model.

Many people have predicted this approach to fail because one of the characteristics of Type 2 diabetes is insulin resistance and so it was generally thought that simply replacing insulin wouldn't be effective, Kieffer added.

Researchers fed four separate groups of immunosuppressed mice a different diet to try to emulate humans diagnosed with Type 2 diabetes. One group of mice received a 45 percent fat diet; one a 60 percent fat diet; one a high-fat, Western diet; and the last a low-fat diet. No single group of mice developed a phenotype that exactly mimicked a Type 2 diabetes human patient, but all three high-fat groups ended up exhibiting characteristics that mirrored the hallmark features of the condition.

Study authors transplanted human embryonic stem cell (hESC)-derived pancreatic progenitor cells into the mice after they began exhibiting symptoms. These cells are programmed to expand and differentiate when transplanted and to subsequently secrete insulin.

To transplant the human cells, researchers used a macroencapsulation device, a mechanism that is meant to prevent the body from detecting nonnative material as foreign and subsequently rejecting it. Because the mice were immunosuppressed, the device wasnt necessary, but Kieffer said his team used it so their findings would be more relevant for future clinical trials, wherein the patients would not be immunosuppressed. Researchers opted to induce Type 2 diabetes symptoms in immunosuppressed mice with diet instead of using a mouse model genetically engineered to assume Type 2 diabetes for that same reason.

The hope in the field is that some sort of device will eliminate the need for immunosuppression when cells are transplanted, Kieffer said.

Read the original here:

Stem cell therapy may help treat type 2 diabetes